Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Verona Pharma plc's RPL554 Demonstrates Positive Airway Anti-Inflammatory Activity In Clinical Trial


Tuesday, 5 Mar 2013 02:10am EST 

Verona Pharma plc announced results of exploratory, placebo-controlled, double-blind clinical trial designed to specifically evaluate the anti-inflammatory properties of RPL554 in healthy subjects challenged with an inhaled irritant. This dual PDE3/4 inhibitor is under development as inhaled treatment for COPD (chronic obstructive pulmonary disease) and asthma. This exploratory study showed a statistically reduction of total cells as well as in various types of inflammatory cells entering the airways in RPL554 treated, compared to placebo treated, subjects. The primary end point chosen for this exploratory trial was a reduction in proportion of neutrophil cells, an inflammatory cell type recognised for central role in COPD and severe asthma, to total inflammatory cells in sputum and secondary endpoints included reductions in total inflammatory cell numbers. While there was a trend in favour of primary endpoint, study narrowly missed reaching statistical significance even though there was a reduction in absolute number of neutrophils. There were also statistically reductions in various types of inflammatory cells entering airways in RPL554 treated subjects, providing positive evidence of the drug's anti-inflammatory effects. Study also showed that drug was well tolerated with adverse events being mild and not significantly different to placebo. Consistent with earlier clinical studies with RPL554, there was no evidence of cardiovascular/gastrointestinal side effects. 

Company Quote

1.1
0.0 +0.00%
25 Jul 2014